3 news items
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
ALXO
9 May 24
.Research and Development ("R&D") Expenses: R&D expenses consist primarily of pre-clinical, clinical
ALX Oncology Appoints Allison Dillon as Chief Business Officer
ALXO
7 May 24
, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ("R/R B-NHL")
ALXO
9 Apr 24
studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans
- Prev
- 1
- Next